Prescription drug prices continue to rise and have become one the most important healthcare issues facing the nation. In an effort to address the problem, President Trump announced his drug pricing plan on May 11. After his remarks, analysts are concerned that it could significantly...

In 2015, the 340B Drug Discount Program saved healthcare providers $6 billion on drug acquisition costs. While the program aims to make pharmaceutical and clinical care affordable and accessible to low-income patients; there is evidence that some participating entities are exploiting its discounts for profit. Since close...

The 340B drug discount program helps disproportionate share hospitals (DSHs) to serve low-income patients. The stated objective of the 340B drug discount program is to “stretch federal resources as far as possible reaching more eligible patients and providing more comprehensive services.” Over time the program...

A recent opinion article by Tara O'Neill Hayes outlines arguments for CMS' "Final 340B Rule." The Centers for Medicare and Medicaid Services greeted the new year by slashing what Medicare pays hospitals for specific drugs by up to 30 percent. Consequently, Hospitals are vehemently against this decision....

Recently, Congress introduced reformed 340B eligibility requirements and has requested more comprehensive reporting on how hospitals utilize savings from the program. Republican Representative Chris Collins initiated the legislative push to overhaul the 340B Drug Discount Program and expects prompt consideration on the House floor. Collins views...

The future of the 340B drug discount program is in jeopardy as the ongoing debate over the program intensifies. Initially, this program aimed to serve low-income patients with access to medications by requiring pharmaceutical companies to discount their drugs for providers. However, in recent years...

A recent report from the National Academies of Sciences, Engineering, and Medicine shows that the need for effective and affordable medicines is being underserved by the biopharmaceutical sector. The report is composed of eight (8) recommendations and twenty-seven (27) strategies aimed to improve prescription drug...